Santos Elton Jonh Freitas, Dias Raimunda Sheyla Carneiro, Lima Janielle Ferreira de Brito, Salgado Filho Natalino, Miranda Dos Santos Alcione
University Hospital of the Federal University of Maranhão, São Luís, Brazil.
Federal University of Maranhão, São Luís, Brazil.
Int J Nephrol Renovasc Dis. 2020 Oct 8;13:231-237. doi: 10.2147/IJNRD.S239151. eCollection 2020.
Anemia is a frequent complication of chronic kidney disease, and its primary cause is erythropoietin deficiency. After diagnosis, treatment begins with administration of an erythropoiesis-stimulating agent (ESA). However, some patients present with resistance to ESA, which needs to be reversed, as it can increase the risk of death in patients with kidney disease. Therefore, we provide a discussion of the current literature regarding the factors that can modify the response to this class of drugs and the strategies that can be considered to optimize the benefits of treating anemia.
贫血是慢性肾脏病的常见并发症，其主要原因是促红细胞生成素缺乏。确诊后，治疗从给予促红细胞生成素刺激剂（ESA）开始。然而，一些患者对ESA存在抵抗，这种抵抗需要被逆转，因为它会增加肾病患者的死亡风险。因此，我们对当前文献进行了讨论，内容涉及可改变对此类药物反应的因素以及可考虑用于优化贫血治疗益处的策略。
